Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095914 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00095914: Completed Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
NCT00095914 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00095914, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining paclitaxel with ABI-007 may kill more tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of combining paclitaxel with ABI-007 in treating patients who have locally advanced or metastatic solid tumors.
Interventions
- DRUG paclitaxel
- DRUG paclitaxel albumin-stabilized nanoparticle formulation
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
What the finished NCT00095914 record still lists
NCT00095914 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00095914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00095914 about?
NCT00095914 is a clinical study titled "Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as paclitaxel and ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining paclitaxel with ABI-007 may kill more tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of combining paclita...
What is the current status of trial NCT00095914?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00095914?
The interventions under investigation include: paclitaxel (DRUG), paclitaxel albumin-stabilized nanoparticle formulation (DRUG).
Who is sponsoring clinical trial NCT00095914?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia